Characterization of ADME properties of [¹⁴C]asunaprevir (BMS-650032) in humans

References

• Armstrong GL, Wasley A, Simard EP, et al. (2006). The prevalence of hepatotitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–14
   PubMed Web of Science ®Google Scholar
• Bolton JL, Trush MA, Penning TM, et al. (2000). Role of quinones in toxicology. Chem Res Toxicol 13:135–60
   PubMed Web of Science ®Google Scholar
• Chayama K, Takahashi S, Toyota J, et al. (2012). Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55:742–8
   PubMed Web of Science ®Google Scholar
• Dahlin DC, Miwa GT, Lu AY, Nelson SD. (1984). N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Nat Acad Sci 81:1327–31
   PubMed Web of Science ®Google Scholar
• Eley T, He B, Huang S-P, et al. (2013). Pharmacokinetics of the NS3 protease inhibitor, asunaprevir (ASV, BMS-650032), in phase I studies in subjects with or without chronic hepatitis C. Clin Pharmacol Drug Dev 2:316–27
   PubMed Web of Science ®Google Scholar
• Ferenci P. (2012). Treatment of chronic hepatitis C – are interferons really necessary? Liver Int 32:108–12
   PubMed Web of Science ®Google Scholar
• Fried MW. (2002). Side effects of therapy of hepatitis C and their management. Hepatology 36:S237–44
   PubMed Web of Science ®Google Scholar
• Goudreau N, Llinàs-Brunet M. (2005). The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs 14:1129–44
   PubMed Web of Science ®Google Scholar
• Hinson JA, Nelson SD, Mitchell JR. (1977). Studies on the microsomal formation of arylating metabolites of acetaminophen and phenacetin. Mol Pharmacol 13:625–33
   PubMed Web of Science ®Google Scholar
• Holler TP, Parkinson T, Pryde DC. (2009). Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin Drug Discov 4:293–314
   PubMed Web of Science ®Google Scholar
• Jiang H, Kandoussi H, Zeng J, et al. (2015). Multiplexed LC–MS/MS method for the simultaneous quantitative determination of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. J Pharm Biomed Anal 107C:409–18
   Google Scholar
• Khalid O, Bacon BR. (2011). Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. Clin Invest 1:1717–29
   Google Scholar
• Kwong AD, Kauffman RS, Hurter P, Mueller P. (2011). Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotech 29:993–1003
   PubMed Web of Science ®Google Scholar
• Kwong AD, McNair L, Jacobson I, George S. (2008). Recent progress in the development of selected hepatitis C virus NS3·4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 8:522–31
   PubMed Web of Science ®Google Scholar
• Laham S, Potvin M. (1983). Biological conversion of N-phenyl-2-naphthylamine to 2-naphthylamine in the Sprague-Dawley rat. Drug Chem Toxicol 6:295–309
   PubMed Web of Science ®Google Scholar
• Li X, Zhang S, Zhang Y-K, et al. (2011). Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorg Med Chem Lett 21:2048–54
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Lawitz E, et al. (2012). Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366:216–24
   PubMed Web of Science ®Google Scholar
• Manns MP, Foster GR, Rockstroh JK, et al. (2007). The way forward in HCV treatment—finding the right path. Nat Rev Drug Discov 6:991–1000
   PubMed Web of Science ®Google Scholar
• McPhee F, Friborg J, Levine S, et al. (2012). Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56:3670–81
   PubMed Web of Science ®Google Scholar
• McPhee F, Levesque PC, Li D, et al. (2010). Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J Hepatol 52:S296
   PubMed Web of Science ®Google Scholar
• McPhee F, Yeung K-S, Good AC, Meanwell NA. (2003). Hepatitis C virus NS3 serine protease as a drug discovery target. Drugs Future 28:465–88
   Web of Science ®Google Scholar
• Mosure KW, Knipe JO, Browning M, et al. (2015). Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor. J Pharm Sci. [Epub ahead of print]. doi:10.1002/jps.24356
   PubMed Web of Science ®Google Scholar
• Munir S, Saleem S, Idrees M, et al. (2010). Hepatitis C treatment: current and future perspectives. Virol J 7:296–301
   PubMed Web of Science ®Google Scholar
• Pasquinelli C, McPhee F, Eley T, et al. (2012). Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 56:1838–44
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–38
   PubMed Web of Science ®Google Scholar
• Poordad F, Khungar V. (2011). Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care 17:S123–30
   PubMed Web of Science ®Google Scholar
• Sato H, Guengerich FP. (2000). Oxidation of 1,2,4,5-tetramethoxybenzene to a cation radical by cytochrome P450. J Am Chem Soc 122:8099–100
   Web of Science ®Google Scholar
• Saxi A. (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55:245–64
   PubMed Web of Science ®Google Scholar
• Sheldon J, Barreiro P, Vincent V. (2007). Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Invest Drugs 16:1171–81
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Njoroge FG. (2009). Macrocyclic inhibitors of HCV NS3 protease. Expert Opin Ther Pat 19:1277–303
   PubMed Web of Science ®Google Scholar
• Williams JA, Cook J, Hurst SI. (2003). A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31:1526–30
   PubMed Web of Science ®Google Scholar
• Zoulim F, Chevallier M, Maynard M, Trepo C. (2003). Clinical consequences of hepatitis C virus infection. Rev Med Virol 13:57–68
   PubMed Web of Science ®Google Scholar